IRIS Peptide Targets BRCA1-IRIS to Restore Chemosensitivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, particularly for breast and ovarian cancers, face challenges with drug resistance and recurrence due to late diagnosis and the development of platinum-resistant recurrence, necessitating novel therapeutic approaches that target drug-resistant tumor cells and restore chemo-sensitivity.

Innovation Solution

The use of a specific peptide, known as the IRIS peptide, which inhibits BRCA1-IRIS expression by silencing it with shRNA or siRNA, combined with chemotherapeutic agents like cisplatin and paclitaxel, to target and reduce BRCA1-IRIS overexpression in cancer cells, thereby sensitizing them to chemotherapy and inhibiting tumor growth and metastasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard chemotherapy treatments (carboplatin and paclitaxel) are used, then initial response is achieved, but drug resistance develops leading to relapse and cancer progression

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidduration of response

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by using peptides to silence BRCA1-IRIS expression before chemotherapy treatment. The peptide treatment is administered prior to or in combination with chemotherapeutic agents to pre-sensitize cancer cells, making them more vulnerable to chemotherapy-induced cell death and preventing the development of platinum-resistant recurrence.

Inventive Principle:

Principle #10Preliminary action

2Productivity

If chemotherapy is administered to treat cancer, then tumor growth is inhibited, but Anoikis resistance develops allowing tumor recurrence

Engineering Contradiction:

Improvetumor growth inhibitionVSAvoidprevention of recurrence

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent uses peptides as intermediary substances that mediate between chemotherapy agents and cancer cells. These peptides silence BRCA1-IRIS expression, acting as a bridge that enhances the effectiveness of chemotherapeutic agents while preventing the development of Anoikis resistance that leads to tumor recurrence.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If BRCA1-IRIS is overexpressed in cancer cells, then tumor growth and metastasis are promoted, but sensitivity to chemotherapy is reduced

Engineering Contradiction:

Improvetumor growth promotionVSAvoidchemotherapy sensitivity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the harmful BRCA1-IRIS protein expression from cancer cells using specific peptides. By silencing BRCA1-IRIS expression through peptide-mediated mechanisms, the patent removes the protective effect that cancer cells gain from this overexpression, thereby restoring sensitivity to chemotherapy agents.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS9303069B2Peptides for treating cancer

Publication Date: 2016.04.05 UNIV OF MISSISSIPPI MEDICAL CENT

AI summary

The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.